Skip to NavigationSkip to content

Bayer and Orion's Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

Published on 31/01/20 at 10:35am

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult male patients.

The data showed that the drug, when combined with androgen deprivation therapy (ADT), demonstrated a “significant improvement” in overall survival benefit compared to placebo with ADT.

This benefit bolsters previous data supporting the combo’s efficacy in metastasis-free survival compared to the placebo combo. However, thus far, the combo has not produced mature data on its benefit in overall survival; these data as well as those on additional endpoints were confirmed to be in the pipeline to be presented at an upcoming scientific meeting.

The combo has already secured approval in the US, Brazil and Japan for this indication.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches